-$2.49 EPS Expected for GW Pharmaceuticals PLC- (GWPH) This Quarter

Wall Street analysts forecast that GW Pharmaceuticals PLC- (NASDAQ:GWPH) will post earnings of ($2.49) per share for the current fiscal quarter, according to Zacks Investment Research. Six analysts have made estimates for GW Pharmaceuticals PLC-‘s earnings, with the highest EPS estimate coming in at ($2.16) and the lowest estimate coming in at ($2.76). GW Pharmaceuticals PLC- reported earnings per share of ($3.12) during the same quarter last year, which would indicate a positive year-over-year growth rate of 20.2%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, May 14th.

On average, analysts expect that GW Pharmaceuticals PLC- will report full-year earnings of ($8.56) per share for the current financial year, with EPS estimates ranging from ($10.20) to ($6.01). For the next financial year, analysts expect that the firm will report earnings of ($3.01) per share, with EPS estimates ranging from ($6.72) to $1.68. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that cover GW Pharmaceuticals PLC-.

Several research analysts recently issued reports on the stock. Zacks Investment Research raised shares of GW Pharmaceuticals PLC- from a “hold” rating to a “strong-buy” rating and set a $198.00 target price on the stock in a research note on Saturday, March 2nd. Morgan Stanley reissued a “buy” rating on shares of GW Pharmaceuticals PLC- in a research note on Tuesday, April 9th. Cantor Fitzgerald reissued an “overweight” rating and set a $196.00 target price (up from $193.00) on shares of GW Pharmaceuticals PLC- in a research note on Monday, March 18th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $185.00 price objective on shares of GW Pharmaceuticals PLC- in a research note on Wednesday, February 27th. Finally, BidaskClub raised shares of GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a research note on Friday, February 15th. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $180.27.

Shares of NASDAQ GWPH opened at $155.87 on Friday. The firm has a market cap of $4.70 billion, a P/E ratio of -14.76 and a beta of 2.80. GW Pharmaceuticals PLC- has a 12-month low of $90.14 and a 12-month high of $182.23. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.34 and a current ratio of 6.66.

In other GW Pharmaceuticals PLC- news, insider Geoffrey W. Dr Guy sold 1,200,000 shares of the firm’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $14.69, for a total value of $17,628,000.00. Following the transaction, the insider now directly owns 8,465,528 shares of the company’s stock, valued at $124,358,606.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Volker Knappertz sold 4,140 shares of the firm’s stock in a transaction on Tuesday, February 26th. The shares were sold at an average price of $12.46, for a total transaction of $51,584.40. Following the completion of the transaction, the insider now directly owns 9,612 shares in the company, valued at $119,765.52. The disclosure for this sale can be found here. Insiders sold 1,895,496 shares of company stock worth $27,538,565 over the last ninety days. Insiders own 5.50% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Belpointe Asset Management LLC raised its holdings in shares of GW Pharmaceuticals PLC- by 6.2% in the fourth quarter. Belpointe Asset Management LLC now owns 1,463 shares of the biopharmaceutical company’s stock valued at $142,000 after purchasing an additional 85 shares during the last quarter. Advisory Services Network LLC raised its holdings in shares of GW Pharmaceuticals PLC- by 23.1% in the fourth quarter. Advisory Services Network LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 96 shares during the last quarter. Horrell Capital Management Inc. raised its holdings in shares of GW Pharmaceuticals PLC- by 33.3% in the fourth quarter. Horrell Capital Management Inc. now owns 400 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 100 shares during the last quarter. Edmond DE Rothschild Holding S.A. raised its holdings in shares of GW Pharmaceuticals PLC- by 16.7% in the fourth quarter. Edmond DE Rothschild Holding S.A. now owns 700 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 100 shares during the last quarter. Finally, Resources Investment Advisors Inc. raised its holdings in shares of GW Pharmaceuticals PLC- by 51.9% in the fourth quarter. Resources Investment Advisors Inc. now owns 366 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 125 shares during the last quarter. Institutional investors own 79.32% of the company’s stock.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Featured Article: Conference Calls and Individual Investors

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC- (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.